SG85628A1 - Compound and its use - Google Patents

Compound and its use

Info

Publication number
SG85628A1
SG85628A1 SG9901252A SG1999001252A SG85628A1 SG 85628 A1 SG85628 A1 SG 85628A1 SG 9901252 A SG9901252 A SG 9901252A SG 1999001252 A SG1999001252 A SG 1999001252A SG 85628 A1 SG85628 A1 SG 85628A1
Authority
SG
Singapore
Prior art keywords
compound
Prior art date
Application number
SG9901252A
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Nigel Arthur Griffith-Skinner
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG85628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SG85628A1 publication Critical patent/SG85628A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG9901252A 1998-06-10 1999-02-25 Compound and its use SG85628A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
SG85628A1 true SG85628A1 (en) 2002-01-15

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9901252A SG85628A1 (en) 1998-06-10 1999-02-25 Compound and its use

Country Status (31)

Country Link
US (1) US6333198B1 (id)
EP (2) EP1170588A1 (id)
JP (1) JP2989189B1 (id)
KR (1) KR100322354B1 (id)
CN (2) CN1238454A (id)
AP (3) AP0102286A0 (id)
AR (1) AR014074A1 (id)
AT (1) ATE218552T1 (id)
AU (1) AU2031999A (id)
BR (1) BR9900984A (id)
CA (1) CA2265194C (id)
DE (1) DE69901656T2 (id)
DK (1) DK0963980T3 (id)
EA (1) EA000666B1 (id)
ES (1) ES2178342T3 (id)
GB (1) GB9812413D0 (id)
HR (1) HRP990074A2 (id)
HU (1) HUP9900592A3 (id)
ID (1) ID22957A (id)
MA (1) MA24777A1 (id)
NO (2) NO991151L (id)
NZ (1) NZ334590A (id)
PE (1) PE20000332A1 (id)
PL (1) PL331870A1 (id)
PT (1) PT963980E (id)
SG (1) SG85628A1 (id)
SI (1) SI0963980T1 (id)
TR (1) TR199900520A2 (id)
UY (1) UY25946A1 (id)
YU (1) YU12399A (id)
ZA (1) ZA991951B (id)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
BR0116553A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
WO2002054062A2 (en) * 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
DE60116514T2 (de) 2000-12-29 2006-08-17 Pfizer Ltd., Sandwich Amlodipinhemimaleat
EP1309555B1 (en) 2000-12-29 2005-07-27 Pfizer Limited Process for making amlodipine maleate
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1708708A1 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
CA2563776A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
EP1740563A2 (en) * 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
US7378553B2 (en) * 2004-06-28 2008-05-27 Teva Pharmaceutical Fine Chemicals S.R.L. Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
JP2008506784A (ja) * 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 結晶形ミコフェノール酸・ナトリウム
WO2006020348A2 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
JP2007513074A (ja) * 2004-09-04 2007-05-24 テバ ファーマシューティカル インダストリーズ リミティド 単離されたバラシクロビル不純物、バラシクロビル不純物の調製方法および参照標準としての使用
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
HRP20090676T1 (hr) * 2005-01-11 2010-01-31 Teva Pharmaceutical Fine Chemicals S.R.L. Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
EP1866295A2 (en) * 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Processes for the preparation of linezolid intermediate
EP1858859A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
CA2600609A1 (en) * 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
EP1866275A1 (en) * 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
JP2008505980A (ja) * 2005-05-10 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド イソブチルグルタル酸を有さないプレガバリン及びその調製方法
EP1879852A1 (en) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Pregabalin free of lactam and a process for preparation thereof
US7763749B2 (en) * 2005-05-10 2010-07-27 Teva Pharmaceutical Industries Ltd. Method for the preparation of Pregabalin and salts thereof
ATE445587T1 (de) 2005-05-23 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
WO2007002722A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. Synthesis of anastrozole and purification of one of its intermediate
US7812168B2 (en) * 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
ES2398579T3 (es) * 2005-09-19 2013-03-20 Teva Pharmaceutical Industries Ltd Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
EP1891034A2 (en) * 2005-12-27 2008-02-27 Teva Pharmaceutical Fine Chemicals S.R.L. Processes for preparing darifenacin hydrobromide
ES2310504T1 (es) * 2006-03-27 2009-01-16 Teva Pharmaceutical Fine Chemicals S.R.L. Procedimiento para la preparacion de clorhidrato de memantina sustancialmente libre de impurezas.
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
TW200815323A (en) * 2006-05-24 2008-04-01 Teva Pharma Processes for the preparation of R-(+)-3-(carbamoylmethyl)-5-methylhexanoic acid and salts thereof
EP2071032A3 (en) * 2006-05-31 2009-07-08 Teva Pharmaceutical Industries Ltd The use of enzymatic resolution for the preparation of intermediates of pregabalin
WO2007143152A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CA2659290A1 (en) * 2006-08-14 2008-02-21 Jean-Paul Roduit A process for the preparation of lamotrigine
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
CA2681313C (en) * 2007-03-22 2012-09-11 Teva Pharmaceutical Industries Ltd. Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
BRPI0803097A2 (pt) * 2007-04-11 2011-11-08 Teva Gyogyszergyar ... método para redução do nìvel de impurezas na fermentação do ácido micofenólico
EP2069320A2 (en) * 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
KR20090101462A (ko) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
US8067423B2 (en) * 2007-10-23 2011-11-29 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
US20090234020A1 (en) * 2008-03-06 2009-09-17 Valarie Niddam-Hildesheim Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2011121452A2 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560B (zh) 2018-05-09 2025-11-25 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR227521A1 (es) 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAILSTAD J.M. & FINDLAY J.W.A.: "Immunofluorometric assay for lamotrigine (Lamictal) in human plasma" THERAPEUTIC DRUG MONITORING, US, RAVEN PRESS, NEW YORK, NY, vol. 13, no. 5, September 1991 (1991-09), pages 433-442, XP000882274 *

Also Published As

Publication number Publication date
AP2001002286A0 (en) 2001-12-31
AP0102286A0 (en) 2000-09-10
EA199900159A1 (ru) 1999-12-29
NZ334590A (en) 2000-07-28
HU9900592D0 (en) 1999-04-28
ATE218552T1 (de) 2002-06-15
NO20032753L (no) 1999-12-13
NO20032753D0 (no) 2003-06-17
PT963980E (pt) 2002-10-31
EP1170588A1 (en) 2002-01-09
AR014074A1 (es) 2001-01-31
AU2031999A (en) 2000-01-06
DK0963980T3 (da) 2002-09-16
HRP990074A2 (en) 2000-10-31
TR199900520A3 (tr) 2000-01-21
CN1238454A (zh) 1999-12-15
CN1306210A (zh) 2001-08-01
EP0963980A2 (en) 1999-12-15
BR9900984A (pt) 2000-05-02
GB9812413D0 (en) 1998-08-05
KR100322354B1 (ko) 2002-02-07
EP0963980A3 (en) 2000-05-31
TR199900520A2 (en) 2000-01-21
ZA991951B (en) 1999-08-16
HUP9900592A2 (hu) 2000-04-28
EP0963980B1 (en) 2002-06-05
KR20000005611A (ko) 2000-01-25
ES2178342T3 (es) 2002-12-16
HUP9900592A3 (en) 2002-04-29
US6333198B1 (en) 2001-12-25
CA2265194C (en) 2000-10-10
SI0963980T1 (en) 2002-12-31
PL331870A1 (en) 1999-12-20
UY25946A1 (es) 2000-12-29
AP9901481A0 (en) 1999-03-31
MA24777A1 (fr) 1999-10-01
JP2000009714A (ja) 2000-01-14
DE69901656D1 (de) 2002-07-11
DE69901656T2 (de) 2003-01-30
NO991151D0 (no) 1999-03-10
ID22957A (id) 1999-12-23
YU12399A (sh) 2002-08-12
NO991151L (no) 1999-12-13
EA000666B1 (ru) 2000-02-28
PE20000332A1 (es) 2000-04-10
JP2989189B1 (ja) 1999-12-13

Similar Documents

Publication Publication Date Title
SG85628A1 (en) Compound and its use
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
EP1102535A4 (en) COMPOUNDS AND METHODS
HU9903361D0 (en) Filter-device with collecting-vessel and with heating-device
IL139145A0 (en) New use
GB9813271D0 (en) Composition and use
ZA985096B (en) Composition compound and use
PL347357A1 (en) Novel composition and use
GB9818914D0 (en) Use
GB9814640D0 (en) New use
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB9817235D0 (en) Compound,composition and use
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
PL332616A1 (en) Hydoxymethylhexanones as odorising and savourising agents
GB9817236D0 (en) Compound,composition and use
EP1058550A4 (en) SUBSTITUTED SEMICARBAZIDES AND THEIR USE
GB9718876D0 (en) Compound,composition and use
GB9803232D0 (en) Compound composition and use
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
GB9817238D0 (en) Compound,composition and use
GB9927927D0 (en) Compound composition and use
GB9828004D0 (en) Use
GB9807503D0 (en) Use
GB9817064D0 (en) New use
GB9817911D0 (en) New use